LATEST PUBMED ARTICLE
• Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture.
• Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.
• Comparison of the Abbott Realtime HIV-1 and HCV viral load assays with commercial competitor assays.
• Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA.
• Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.
LATEST PRESS RELEASE
Leading international clinical research organisation targeting growth and expansion of expertise and services
Parcom Capital has acquired the successful clinical research organisation Viroclinics Biosciences. Viroclinics believes Parcom is the perfect partner to help it realise its growth ambitions. Viroclinics employs more than 100 experts and works for clients across the world. The acquisition will give Viroclinics the opportunity to expand its fields of expertise and its portfolio of services.
Rotterdam, 29 August 2017
Viroclinics was founded in 2001 and specialises in testing new vaccines and drugs in the clinical trial stages prior to their market launch. Viroclinics has clients across the globe and conducts virology testing for clients that include the world’s top 10 biopharmaceutical companies. The company is also a market leader in the Netherlands. For instance, Viroclinics tests around 90 percent of all anti-influenza medications developed worldwide. The company expects to see further growth in other fields of virology in the coming years.
Bob van Gemen, CEO Viroclinics Biosciences, is pleased with the acquisition by Parcom Capital. “Our main focus at the moment is the research and treatment of respiratory viruses. We would like to broaden our portfolio, especially in the area of other viral targets, such as hepatitis, polio and RSV. For instance, we are very closely involved in a project that is on the verge of eradicating the polio virus for good. In Parcom Capital, we have found a new, solid partner who will enable us to realise even more of our ambitious targets. In the coming years, we will enter a new phase as a company and we have major growth ambitions.”
As a result of the sale, Viroclinics is now fully owned by Parcom Capital. Parcom has made several investments in successful Dutch companies in recent years, including the mobile telecom provider Simpel.nl, Star Group and RH Marine. “We see Viroclinics as a valuable addition to our portfolio,” says Parcom Capital partner Piet-Hein de Jager. “We believe very strongly in the growth opportunities for Viroclinics, which has acquired a leading position in the biopharma market with its expertise and innovative approach.”
Gilde Healthcare Service is the selling party and was advised in the acquisition process by William Blair. Parcom was advised by PricewaterhouseCoopers. The acquisition has no consequences for the employees of Viroclinics. The parties decline to publish any financial details.
Viroclinics Biosciences BV (Viroclinics) is the globally preferred institute for virology testing. Before new and amended drugs are launched in the market, Viroclinics conducts laboratory tests to assess their safety and efficacy. Viroclinics’ clients include the larger pharmaceutical development companies, producers and contract organisations that develop anti-viral drugs and vaccines. More information is available on the website www.viroclinics.eu.
About Parcom Capital and Management
Parcom Capital and Management is a leading mid-market private equity fund that has been investing in high-grade companies since 1982. The fund manages more than EUR 1 billion in investments in a range of sectors. In 2016, Parcom was acquired by the partners in the firm via a management buy-out and hived off from insurance firm NN. Parcom’s most recent fund raised capital of EUR 550 million. More information: www.parcomcapital.com